{"url_path":"/sec/fate/8-k/2026-06-15/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-15","source_url":"https://www.sec.gov/Archives/edgar/data/1434316/0001193125-26-271055-index.html","accession_number":"0001193125-26-271055","cik":"0001434316","ticker":"FATE","issuer_name":"FATE THERAPEUTICS INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/1434316/0001193125-26-271055-index.html","primary_entity_key":"0001434316","primary_entity_name":"FATE THERAPEUTICS INC"},"word_count":89,"has_tables":true,"body_markdown":"## Item 9.01 Financial Statements and Exhibits.\n\n(d) Exhibits.\n\nExhibit No.\n\nDescription\n\n10.1\n\n[Third Amended and Restated 2022 Stock Option and Incentive Plan and form agreements thereunder](fate-ex10_1.htm)\n\n104\n\nCover Page Interactive Data File (embedded within the Inline XBRL document)\n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \n\nFATE THERAPEUTICS, INC.\n\n \n\n \n\n \n\n \n\nDate:\n\nJune 15, 2026\n\nBy:\n\n/s/ Bahram Valamehr\n\n \n\n \n\n \n\nBahram Valamehr, Ph.D., MBA\nPresident and Chief Executive Officer"}